The contribution of early nephropathy to cardiovascular risk

Cardiology Clinics
Tamar S Polonsky, Francesco Locatelli

Abstract

Patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min per 1.72 m(2), and presence of microalbuminuria (MA), have an increased risk of cardiovascular (CV) events, compared with patients with normal renal function. The strength of the association among patients with a mild reduction in eGFR depends largely on the population studied, whereas the data regarding MA show an elevated risk among both low- and high-risk populations. Patients with mildly reduced eGFR or MA experience a reduction in CV events and progression of renal disease with treatment of CV risk factors. For patients who experience a myocardial infarction, observational data suggest that patients with a mildly reduced eGFR also have improved outcomes with an early invasive strategy, compared with a noninvasive strategy. However, whether targeting therapy to normalize renal function also confers a reduction in CV events remains unknown.

References

Nov 16, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·K R TuttleR Short
Apr 25, 2000·Hypertension·J S JensenK Borch-Johnsen
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Feb 7, 2003·Journal of the American College of Cardiology·Guruprasad ManjunathMark J Sarnak
Jul 16, 2003·Annals of Internal Medicine·Andrew S LeveyUNKNOWN National Kidney Foundation
Oct 29, 2003·Circulation·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Oct 20, 2004·Circulation·Folkert W AsselbergsUNKNOWN Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators
Nov 16, 2005·Hypertension·George L BakrisUNKNOWN GEMINI Investigators
Dec 22, 2005·American Heart Journal·Daniel J BlackmanVladimir Dzavik
Feb 8, 2006·Annals of Internal Medicine·Mahboob RahmanUNKNOWN ALLHAT Collaborative Research Group
Jul 11, 2006·Journal of the American Society of Nephrology : JASN·Coen D A Stehouwer, Yvo M Smulders
Oct 20, 2006·Journal of Human Hypertension·S CottoneG Cerasola
Aug 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Matthew R Weir
Oct 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·James ShepherdUNKNOWN Treating to New Targets Investigators
Nov 16, 2007·Journal of the American Society of Nephrology : JASN·Grace L SmithChirag R Parikh
Nov 21, 2007·Circulation·Scott D SolomonUNKNOWN Prevention of Events With ACE Inhibition (PEACE) Investigators
Apr 1, 2008·The American Journal of Medicine·Pantelis A SarafidisGeorge L Bakris
Aug 13, 2008·Current Opinion in Nephrology and Hypertension·Irena Duka, George Bakris
Dec 5, 2008·The New England Journal of Medicine·Kenneth JamersonUNKNOWN ACCOMPLISH Trial Investigators
May 16, 2009·Journal of the American Society of Nephrology : JASN·Toshiharu NinomiyaUNKNOWN ADVANCE Collaborative Group
Jul 1, 2009·BMJ : British Medical Journal·Tobias KurthPaul M Ridker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cell Adhesion Molecules in AS

Cell adhesion molecules expressed on the vascular endothelium and circulating leukocytes in response to inflammatory stimuli are implicated in atherosclerosis. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.